Enforcement Report - Week of August 23, 2023
Alembic and Aurobindo Pharma, the U.S. unit of India’s Aurobindo, issued voluntary recalls of products because of quality issues and manufacturing deficiencies, respectively.
Enforcement Report - Week of June 7, 2023
Enforcement Report - Week of February 1, 2023
Enforcement Report - Week of January 25, 2023
LEDGEWOOD, N.J.--(BUSINESS WIRE)--ImprimisRx, America’s #1 Ophthalmic Pharmacy™, today announced the availability of Fortisite™, which includes a patent-pending compounded combination of Tobramycin 1.5% and Vancomycin 5%.
Mankind's Generic Tobramycin Receives Approval in the U.S.
Enforcement Report - Week of June 15, 2022
ALLEGAN, Mich., March 21, 2022 /PRNewswire/ -- Padagis today announced the FDA approval and launch of an AB-rated generic version of Tobradex® Ophthalmic Suspension.
Padagis' Generic Tobramycin and Dexamethasone Receives Approval in the U.S.